INTELLIGENT BIO SOLUTIONS INC.
For the period ended Jun 30, 2026. Filed Aug 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Aug 19, 2026
INBS$2.25-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended June 30, | ||||
|---|---|---|---|---|
| 2026 · 2025 | ||||
| Cash flows from operating activities | ||||
| Net loss | $(12,468,672) | $(10,604,886) | ||
| Adjustments to reconcile net loss to cash used in operating activities: | ||||
| Depreciation and amortization | 1,163,847 | 1,207,875 | ||
| Impairment of long-lived assets | 298,555 | 220,062 | ||
| Provision for credit losses | 9,974 | 546 | ||
| Inventory write-downs | 62,044 | - | ||
| Stock-based compensation | 195,208 | 238,045 | ||
| Non-cash adjustment on R&D expenditure claims | 124,924 | (137,696) | ||
| Non-cash other operating activities | (87,933) | 119,519 | ||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | (253,850) | (164,910) | ||
| Inventories | 216,638 | 142,322 | ||
| Grant receivable / deferred grant income | - | (2,486,668) | ||
| Research and development tax incentive receivable | (72,543) | (209,076) | ||
| Other current assets | (203,956) | (329,404) | ||
| Accounts payable and accrued expenses | (684,743) | 2,577,151 | ||
| Long-term employee benefit liabilities | (34,990) | 21,306 | ||
| Operating lease liabilities | (191,725) | (271,499) | ||
| Net cash used in operating activities | (11,927,222) | (9,677,313) | ||
| Cash flows from investing activities | ||||
| Proceeds from sale of assets held for sale | 40,158 | - | ||
| Purchase of property and equipment | (125,731) | (231,838) | ||
| Net cash used in investing activities | (85,573) | (231,838) | ||
| Cash flows from financing activities | ||||
| Proceeds from issuance of common stock, net of issuance costs | 10,699,794 | 4,589,866 | ||
| Proceeds from issuance of common stock for warrants exercised, net of issuance costs | 4,283,912 | 7,939 | ||
| Net cash provided by financing activities | 14,983,706 | 4,597,805 | ||
| Effect of foreign exchange rates on cash and cash equivalents | 1,492 | 27,157 | ||
| Net increase (decrease) in cash and cash equivalents | 2,972,403 | (5,284,189) | ||
| Cash and cash equivalents, beginning of period | 1,019,909 | 6,304,098 | ||
| Cash and cash equivalents, end of the period | $3,992,312 | $1,019,909 | ||
| Non-cash investing and financing activities | ||||
| Equity issuance costs in accounts payable and accrued expenses | $ | - | $14,999 | |
| Operating lease assets obtained in exchange for operating lease liabilities | $1,928,398 | $ | - | |
| Issuance of common stock upon cashless exercise of Series F warrants | $ | - | $55 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.